Table 1.
Baseline demographic, clinical and behavioral characteristics and bone mineral density of participants by tertile of age. Data presented as unadjusted mean (SD) for continuous data and % of sample for categorical data.
| Youngest-old (n=37) | Middle-old (n=35) | Oldest-old (n=34) | ||
|---|---|---|---|---|
| Characteristic | Mean (SD) or % sample |
Mean (SD) or % sample |
Mean (SD) or % sample |
p- value* |
| Age | 55.8 (1.7) | 61.2 (1.9) | 70.4 (4.8) | <0.01 |
| Comorbidity Index | 1.9 (1.9) | 1.8 (1.9) | 1.6 (1.2) | 0.79 |
| BMI (kg/m2) | 29.0 (6.0) | 31.2 (5.9) | 28.3 (4.8) | 0.08 |
| Time since diagnosis (months) | 47.4 (21.4)† | 58.2 (33.1) | 77.4 (49.0) | <0.01 |
| Stage 0 (%) | 3% | 10% | 5% | 0.64 |
| Stage I (%) | 45% | 39% | 45% | |
| Stage II (%) | 45% | 45% | 45% | |
| Stage IIIa (%) | 7% | 6% | 5% | |
| Received chemotherapy (%) | 71% | 62% | 51% | 0.23 |
| Received radiation therapy (%) | 77% | 88% | 95% | 0.08 |
| Currently taking AI (%) | 26% | 50% | 48% | 0.07 |
| Currently taking SERM (%) | 29% | 6% | 12% | |
| Energy expenditure (kcal/d)a | 254 (197) | 240 (244) | 194 (256) | 0.53 |
| Energy intake (kcal/d) | 1468 (456) | 1401 (565) | 1389 (504) | 0.78 |
| Calcium intake (mg/day)b | 741 (286) | 664 (282) | 764 (361) | 0.38 |
| Exercise adherencec | 70% | 74% | 76% | 0.72 |
| Total hip BMD (g/cm2) | 0.891 (0.101) | 0.868 (0.090) | 0.843 (0.092) | 0.11 |
| Greater trochanter BMD (g/cm2) | 0.672 (0.085) | 0.673 (0.080) | 0.634 (0.087) | 0.10 |
| Femoral neck BMD (g/cm2) | 0.768 (0.101)† | 0.737 (0.092) | 0.710 (0.077) | 0.03 |
Energy expenditure calculated from CHAMPS physical activity survey and includes energy expended in moderate-vigorous intensity activities
Calcium intake includes calcium obtained both from dietary sources and from dietary supplements.
Adherence calculated as % of supervised classes attended across one-year study on those participants completing baseline and final time points (n=67)
p-value comparing age groups using one-way ANOVA for continuous variables or chi-squares test for categorical variables. For outcomes of cancer stage and adjuvant hormone therapy use comparisons tested for differences in the distribution of each variable among age groups.
youngest-old tertile significantly different from oldest-old tertile, p<0.05